Cargando…
Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene trans...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701864/ https://www.ncbi.nlm.nih.gov/pubmed/34946913 http://dx.doi.org/10.3390/genes12121963 |
_version_ | 1784621106107252736 |
---|---|
author | Alkhatabi, Heba Bin Saddeq, Haneen Abdulfattah Alyamani, Luay Shinawi, Thoraia Yasin, Elrashed B. Alserihi, Raed Felimban, Raed Tayeb, Hossam H. Mimani, Rawan Alalla, Zainab Abu-Elmagd, Muhammad Abuzenadah, Adel |
author_facet | Alkhatabi, Heba Bin Saddeq, Haneen Abdulfattah Alyamani, Luay Shinawi, Thoraia Yasin, Elrashed B. Alserihi, Raed Felimban, Raed Tayeb, Hossam H. Mimani, Rawan Alalla, Zainab Abu-Elmagd, Muhammad Abuzenadah, Adel |
author_sort | Alkhatabi, Heba |
collection | PubMed |
description | Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators. |
format | Online Article Text |
id | pubmed-8701864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87018642021-12-24 Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia Alkhatabi, Heba Bin Saddeq, Haneen Abdulfattah Alyamani, Luay Shinawi, Thoraia Yasin, Elrashed B. Alserihi, Raed Felimban, Raed Tayeb, Hossam H. Mimani, Rawan Alalla, Zainab Abu-Elmagd, Muhammad Abuzenadah, Adel Genes (Basel) Article Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators. MDPI 2021-12-09 /pmc/articles/PMC8701864/ /pubmed/34946913 http://dx.doi.org/10.3390/genes12121963 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alkhatabi, Heba Bin Saddeq, Haneen Abdulfattah Alyamani, Luay Shinawi, Thoraia Yasin, Elrashed B. Alserihi, Raed Felimban, Raed Tayeb, Hossam H. Mimani, Rawan Alalla, Zainab Abu-Elmagd, Muhammad Abuzenadah, Adel Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia |
title | Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia |
title_full | Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia |
title_fullStr | Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia |
title_full_unstemmed | Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia |
title_short | Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia |
title_sort | investigation of isocitrate dehydrogenase 1 and 2 mutations in acute leukemia patients in saudi arabia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701864/ https://www.ncbi.nlm.nih.gov/pubmed/34946913 http://dx.doi.org/10.3390/genes12121963 |
work_keys_str_mv | AT alkhatabiheba investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT binsaddeqhaneenabdulfattah investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT alyamaniluay investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT shinawithoraia investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT yasinelrashedb investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT alserihiraed investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT felimbanraed investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT tayebhossamh investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT mimanirawan investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT alallazainab investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT abuelmagdmuhammad investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia AT abuzenadahadel investigationofisocitratedehydrogenase1and2mutationsinacuteleukemiapatientsinsaudiarabia |